Co-founder and CEO, BridGene Biosciences
Dr. Cao has over 20 years of biopharma industry experience in both large and small molecule drug discovery research. He is an expert in biophysical/biochemical characterization of proteins/peptides, focusing on leveraging mass spectrometry to support the biopharmaceutical pipeline. Most recently, Dr. Cao was a Principal Scientist in the Discovery Analytical Attributes Group at Amgen, Inc. His group engaged in hypothesis-driven targeted proteomics to complement Amgen’s genetic discovery platform, with the goal of facilitating seamless and rapid advancement of projects from research to commercialization. Dr. Cao received his Ph.D. from the University of Texas at Austin in Analytical Chemistry and did his Postdoctoral fellowship at Genentech, Inc. He also holds an M.S. in Chemical Engineering from SINOPEC Research Institute of Petroleum Processing in China, as well as a B.S. in Physical Chemistry from Shandong University in Jinan, China.